| Literature DB >> 31729076 |
Johnny Cai1, Jessica Ribkoff2, Sven Olson3, Vikram Raghunathan3, Hanny Al-Samkari4, Thomas G DeLoughery3, Joseph J Shatzel3.
Abstract
Clinically significant bleeding can occur as a consequence of surgery, trauma, obstetric complications, anticoagulation, and a wide variety of disorders of hemostasis. As the causes of bleeding are diverse and not always immediately apparent, the availability of a safe, effective, and non-specific hemostatic agent is vital in a wide range of clinical settings, with antifibrinolytic agents often utilized for this purpose. Tranexamic acid (TXA) is one of the most commonly used and widely researched antifibrinolytic agents; its role in postpartum hemorrhage, menorrhagia, trauma-associated hemorrhage, and surgical bleeding has been well defined. However, the utility of TXA goes beyond these common indications, with accumulating data suggesting its ability to reduce bleeding and improve clinical outcomes in the face of many different hemostatic challenges, without a clear increase in thrombotic risk. Herein, we review the literature and provide practical suggestions for clinical use of TXA across a broad spectrum of bleeding disorders.Entities:
Keywords: antifibrinolytic agents; coagulants; fibrin modulating agents; heavy menstrual bleeding; hematologic agents; hematologic disorders; hemophilia; hemorrhage; hemostatic; postpartum hemorrhage; tranexamic acid; trauma
Year: 2019 PMID: 31729076 PMCID: PMC7023891 DOI: 10.1111/ejh.13348
Source DB: PubMed Journal: Eur J Haematol ISSN: 0902-4441 Impact factor: 2.997